In order to bring you the best possible user experience, this site uses Javascript. If you are seeing this message, it is likely that the Javascript option in your browser is disabled. For optimal viewing of this site, please ensure that Javascript is enabled for your browser.

The free consultation period for this content is over.

It is now only available year-round to EAPC Ivory (& above) Members, Fellows of the ESC and Young combined Members

Pleiotropic effects of rosuvastatin in patients with chronic obstructive pulmonary disease and dyslipidemia

Session Poster Session III - Friday 08:30 - 12:30

Speaker Elena Samorukova

Event : ESC Preventive Cardiology (Formerly EuroPrevent) 2015

  • Topic : preventive cardiology
  • Sub-topic : Lipids
  • Session type : Poster Session

Authors : E Samorukova (Moscow,RU), G Rosliakova (Moscow,RU), T Adasheva (Moscow,RU), V Zadionchenko (Moscow,RU)

E Samorukova1 , G Rosliakova2 , T Adasheva1 , V Zadionchenko1 , 1Moscow State Medical and Dental University, Therapy and family medicine - Moscow - Russian Federation , 2City Hospital of St. Vladimir, laboratory diagnostics - Moscow - Russian Federation ,


Purpose: to analyze the 3-Hydroxy-3-Methyl-Glutaryl Coenzyme A (HMG-CoA) reductase inhibitor rosuvastatin influence on chronic low-grade systemic inflammation, endothelia dysfunction and clinical current in patients with chronic obstructive pulmonary disease (COPD).

Methods: we investigated 60 patients men (age 64 ± 7,6 years) with COPD II-III stages (Global Initiative for Chronic Obstructive Lung Disease 2011) in remission period. The patients were without myocardial infarction, stroke, coronary artery disease. We used of a risk estimation system such as SCORE (Systematic Coronary Risk Estimation) to estimate total cardiovascular risk our patients. A calculated SCORE was 11.31±4 (high and very high risk). The patients were divided into 2 groups. One group (40 patients) received rosuvastatin 5-10 mg during one year. The other group was control (20 patients). The target level for low-density lipoprotein-cholesterol (LDC-?) was = 1,8 mmol/l. The basic therapy COPD did not change. The patients used the combination of anticholinergic agents (ipratropium bromide, tiotropium bromide) with beta-2-adrenomimetic fenoterol. High sensitivity C-reactive protein (hs-CRP), vascular cell adhesion molecule type 1 (VCAM-1) were estimated before and after the treatment period. We analyzed spirometry (severity of airflow limitation), quantity of exacerbations. The symptoms of COPD, health status were analyzed using the St. George’s Respiratory Questionnaire (SGRQ) before and after the rosuvastatin treatment.

Results: all patients reached target values LDC-?. Hs-CRP decreased from 4.5 [3,3; 8,77] mg/l to 3,2 [1,2; 4,1] mg/l (p<0,001). VCAM-1 – marker of endothelial dysfunction decreased from 1066,6 [870; 1381] ng/ml to 795,2 [(670; 1020] ng/ml (p<0,001). The symptoms activity of COPD decreased from 76,3 ± 23,1 to 60,8±11,3 (p<0,05). There was a 21% decrease of COPD exacerbations (p < 0,001). Forced expiratory volume in 1 second (FEV1) 5.2% increase was revealed (p=0,002). The control group did not have statistically significant dynamics in a year. Conclusions: rosuvastatin has anti-inflammatory and endothelial protective effects, improves lung function, and reduces the exacerbations number in patients with COPD. It is important because chronic systemic inflammation and endothelia dysfunction are basic mechanisms of vascular impairments and development of cardiovascular diseases in patients with COPD.

Members get more

Join now
  • 1ESC Professional Members – access all resources from general ESC events 
  • 2ESC Association Members (Ivory, Silver, Gold) – access your Association’s resources
  • 3Under 40 or in training - with a Combined Membership, access all resources
Join now

Our sponsors

ESC 365 is supported by Bayer, Boehringer Ingelheim and Lilly Alliance, Bristol-Myers Squibb and Pfizer Alliance, Novartis Pharma AG and Vifor Pharma in the form of educational grants. The sponsors were not involved in the development of this platform and had no influence on its content.

logo esc

Our mission: To reduce the burden of cardiovascular disease

Who we are